ARCHIVES

Phase II Study Of Pfizer Drug Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 32 No. 4 | April 24, 2009

Download PDF Visit The Full Archive

Related Articles

Professional Societies: ASCO Seeks Balance In Roles As U.S., International Society

May 23, 1997

Blinatumomab Shows Response In Adults with Refractory ALL

May 25, 2012

Stories On Proscar Cause Confusion In Prostate Cancer Prevention Trial

September 6, 1996

NCI Plans $175 Million In Program Cuts To Cover Deficit, Fund New Initiatives

November 17, 2006

NCI Programs: Institute Funds 24 DNA Microarray Centers

September 24, 1999

DeVita Defends CHP Awards, Says Program Has High Priority

September 5, 1980